These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 32998547)

  • 1. Is Testosterone an Effective Hormonal Therapy for Women With Antidepressant-Resistant Major Depression?
    Mathew SJ
    Am J Psychiatry; 2020 Oct; 177(10):891-894. PubMed ID: 32998547
    [No Abstract]   [Full Text] [Related]  

  • 2. Parallel-group placebo-controlled trial of testosterone gel in men with major depressive disorder displaying an incomplete response to standard antidepressant treatment.
    Pope HG; Amiaz R; Brennan BP; Orr G; Weiser M; Kelly JF; Kanayama G; Siegel A; Hudson JI; Seidman SN
    J Clin Psychopharmacol; 2010 Apr; 30(2):126-34. PubMed ID: 20520285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
    J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy.
    Richards C; Iosifescu DV; Mago R; Sarkis E; Reynolds J; Geibel B; Dauphin M
    J Psychopharmacol; 2017 Sep; 31(9):1190-1203. PubMed ID: 28857719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
    Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study.
    Reeves H; Batra S; May RS; Zhang R; Dahl DC; Li X
    J Clin Psychiatry; 2008 Aug; 69(8):1228-1236. PubMed ID: 18681749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
    Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
    CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.
    Earley WR; Guo H; Németh G; Harsányi J; Thase ME
    Psychopharmacol Bull; 2018 Jun; 48(4):62-80. PubMed ID: 30618475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder.
    Mathew SJ; Gueorguieva R; Brandt C; Fava M; Sanacora G
    Neuropsychopharmacology; 2017 Dec; 42(13):2567-2574. PubMed ID: 28553836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial.
    Ionescu DF; Bentley KH; Eikermann M; Taylor N; Akeju O; Swee MB; Pavone KJ; Petrie SR; Dording C; Mischoulon D; Alpert JE; Brown EN; Baer L; Nock MK; Fava M; Cusin C
    J Affect Disord; 2019 Jan; 243():516-524. PubMed ID: 30286416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post hoc analysis of the efficacy and safety of desvenlafaxine 50 mg/day in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
    Kornstein SG; Clayton A; Bao W; Guico-Pabia CJ
    Menopause; 2014 Aug; 21(8):799-806. PubMed ID: 24448103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do estradiol levels influence on the cognitive function during antidepressant treatments in post-menopausal women with major depressive disorder? A comparison with pre-menopausal women.
    Pae CU; Mandelli L; Han C; Ham BJ; Masand PS; Patkar AA; Steffens DC; De Ronchi D; Serretti A
    Neuro Endocrinol Lett; 2008 Aug; 29(4):500-6. PubMed ID: 18766158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder.
    Simon JS; Nemeroff CB
    J Clin Psychiatry; 2005 Oct; 66(10):1216-20. PubMed ID: 16259533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
    Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P
    J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects.
    Levitan RD; Shen JH; Jindal R; Driver HS; Kennedy SH; Shapiro CM
    J Psychiatry Neurosci; 2000 Sep; 25(4):337-46. PubMed ID: 11022398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.
    Kornstein SG; Clayton AH; Bao W; Guico-Pabia CJ
    J Womens Health (Larchmt); 2015 Apr; 24(4):281-90. PubMed ID: 25860107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
    El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial.
    Mischoulon D; Witte J; Levy M; Papakostas GI; Pet LR; Hsieh WH; Pencina MJ; Ward S; Pollack MH; Fava M
    J Clin Psychiatry; 2012 Mar; 73(3):353-7. PubMed ID: 21939613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testosterone levels and sexual function disorders in depressive female patients: effects of antidepressant treatment.
    Kumsar Ş; Kumsar NA; Sağlam HS; Köse O; Budak S; Adsan Ö
    J Sex Med; 2014 Feb; 11(2):529-35. PubMed ID: 24286389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of augmentation strategies for patients with major depressive disorder.
    Fleurence R; Williamson R; Jing Y; Kim E; Tran QV; Pikalov AS; Thase ME
    Psychopharmacol Bull; 2009; 42(3):57-90. PubMed ID: 19752841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.